drugset / Trial / NCT06405490
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.
Timeline
- Start
- 2024-04-17
- Primary completion
- 2026-08-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Nanoliposomal Irinotecan | Unknown | 47.1 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 70 mg/m2 | Intravenous |